 of dextran use among patients undergoing CEA, objective clinical beneﬁt has not been
deﬁnitively demonstrated. Further, in a recent review
of the Vascular Study Group of New England, including
89 surgeons and 66641 CEA procedures performed
from 2003 to 2020, intraoperative dextran administration did not decrease the rate of perioperative stroke,
but it was associated with an increased incidence of
post